MacroGenics (MGNX) Given Coverage Optimism Rating of 0.06

Headlines about MacroGenics (NASDAQ:MGNX) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm identifies positive and negative news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. MacroGenics earned a news impact score of 0.06 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 47.0687194227747 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

These are some of the news articles that may have impacted Accern’s rankings:

MacroGenics (NASDAQ MGNX) traded up $1.06 during trading on Friday, hitting $18.68. 285,600 shares of the stock traded hands, compared to its average volume of 261,654. MacroGenics has a 52-week low of $14.36 and a 52-week high of $31.85.

MacroGenics (NASDAQ:MGNX) last released its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($1.28) earnings per share for the quarter, missing the consensus estimate of ($1.09) by ($0.19). The firm had revenue of $1.70 million during the quarter, compared to the consensus estimate of $5.50 million. MacroGenics had a negative return on equity of 69.31% and a negative net margin of 1,526.55%. The company’s revenue for the quarter was down 48.5% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.97) EPS. research analysts expect that MacroGenics will post -4.24 EPS for the current year.

MGNX has been the topic of several recent research reports. Cowen and Company restated a “buy” rating on shares of MacroGenics in a research report on Wednesday, October 25th. SunTrust Banks, Inc. restated a “buy” rating and set a $26.00 target price on shares of MacroGenics in a research report on Friday, September 1st. Zacks Investment Research downgraded MacroGenics from a “hold” rating to a “sell” rating in a research report on Wednesday, October 4th. Wedbush restated an “outperform” rating and set a $44.00 target price on shares of MacroGenics in a research report on Monday, September 11th. Finally, BidaskClub downgraded MacroGenics from a “hold” rating to a “sell” rating in a research report on Monday, July 31st. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and nine have issued a buy rating to the company. MacroGenics presently has a consensus rating of “Buy” and an average price target of $30.10.

TRADEMARK VIOLATION NOTICE: This piece was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The legal version of this piece can be viewed at

In other news, SVP Jon Marc Wigginton sold 10,000 shares of the company’s stock in a transaction on Wednesday, October 25th. The shares were sold at an average price of $20.00, for a total value of $200,000.00. Following the transaction, the senior vice president now owns 40,000 shares of the company’s stock, valued at $800,000. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 8.30% of the company’s stock.

About MacroGenics

MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies.

Insider Buying and Selling by Quarter for MacroGenics (NASDAQ:MGNX)

Receive News & Ratings for MacroGenics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics Inc. and related companies with's FREE daily email newsletter.

Leave a Reply